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Abstract. The chemical and biochemical route to the synthesis of the 21st amino acid in living systems, 
selenocysteine, is described. The incorporation of this rare amino acid residue into proteins is described 
with emphasis on the role of monoselenophosphate as selenium source. The role of selenocysteine moiety in 
natural mammalian enzymes such as glutathione peroxidase (GPx), iodothyronine deiodinase (ID) and 
thioredoxin reductase (TrxR) is highlighted and the effect of other amino acid residues located in close 
proximity to selenocysteine is described. It is evident from various studies that two amino acid residues, 
tryptophan and glutamine, appear in identical positions in all known members of the GPx family. Ac-
cording to the three-dimensional structure established for bovine GPx, these residues could constitute a 
catalytic triad in which the selenol group of the selenocysteine is both stabilized and activated by hydro-
gen bonding with the imino group of the tryptophan (Trp) residue and with the amido group of the gluta-
mine (Gln) residue. The ID enzymes, on the other hand, do not possess any Trp or Gln residues in close 
proximity to selenium, but contain several histidine residues, which may play important roles in the ca-
talysis. The TrxR enzymes also possess some basic histidines, but the most important amino acid residues 
are the cysteines which constitute the internal cofactor systems along with the catalytically active seleno-
cysteine. The catalytic activity and substrate specificity of all three selenoenzymes are described. The re-
activity of selenocysteine residues in selenoenzymes towards metal-base  drugs such as goldthioglucose 
is also described. 
 
Keywords. Antioxidants; cysteine; deiodination; monoselenophosphate; selenium selenocysteine, sel no-
enzymes, thyroxine. 
1. Introduction 
Selenium was discovered in 1818 by the Swedish 
chemist Berzelius and was named after the Greek moon 
goddess, Selene.1 This main group element belongs 
to group 16 of the periodic table and in nature it is 
associated with sulphur in a ratio between 1 : 103 a d
1 : 105. In biology, selenium, in contrast to sulphur, was 
long considered a poison until Schwarz and Foltz 
identified it as  micronutrient for bacteria, mammals, 
and birds.2 After 15 years of empirical studies on sele-
nium-deficiency syndrome in experimental animals, 
selenium biochemistry came of age in 1973 when two 
bacterial enzymes, formate dehydrogenase3 and gly-
cine reductase,4 were reported to contain selenium. 
At the same time, the biochemical role of selenium 
in mammals was clearly established by the discov-
ery that it is part of the active site of the antioxidant 
enzyme glutathione peroxidase (GPx).5,6 The number 
of selenoproteins identified has grown substantially 
in recent years (table 1).7,8 In prokaryotes, formate 
dehydrogenases,9 hydrogenases,10–12 and glycine r-
ductase13,14 are a few representative examples in which 
selen cysteine15,16 has been verified as the selenium 
moiety. In contrast, selenium is bound to a cysteine 
residue in CO dehydrogenase, where it forms a redox 
active centre with cofactor-bound molybdenum.17 In 
eukaryotes, iodothyronine deiodinases,18–21 thioredoxin 
reductases,22–27 selenophosphate synthetase,26 and 
selenoprotein P28 represent important classes of s-
lenoenzymes in addition to the well-known gluta-
thione peroxidases.5,6,29–32 Many books and reviews 
available in the literature describe various biological 
functions of selenium, including nutritio al impor-
tance.33–38 The purpose of this article is to give an 
overview of the chemical aspects of selen cysteine 
in the active sites of mammalian selenoenzymes. 
2. Selenocysteine – The 21st amino acid 
The major biological form of selenium is represented 
by the amino acid selenocysteine (Sec). The selenol 
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Table 1. Selenocysteine-containing enzymes and their biological functions. 
Enzyme Reaction 
 
Formate dehydrogenases HCOOH ® CO2 + 2H
+ + 2e– 
NiFeSe-hydrogenases H2 ® 2H
+ + 2e– 
Glycine reductase Gly + 2e– + 4H+ + ADP + Pi ® acetete + NH
+
4
 + ATP 
Selenophosphate synthatase HSe– + ATP ® HSe-PO3H2 + AMP + Pi 
Glutathione peroxidases (GPx) H2O2 + 2GSH ® H2O + GSSG 
Phospholipid-hydroperoxide-GPx ROOH + 2GSH ® R-OH + H2O + GSSG 
Type I iodothyronine deio inase L-Thyroxine + 2e– + H+ ® 3,5,3¢-triiodothyronine + I– 
Thioredoxin reductase NADPH + Trxox ® NADP
+ + Trxred 
Selenoprotein W ? 
Selenoprotein P Antioxidant? 
GSH: reduced glutathione, ROOH: Lipid hydroperoxide, Trx: thioredoxin 
 
 
group in the free amino acid (1) is unstable and readily 
oxidizes in air to the corresponding diselenide (2). 
However, the diselenide can be easily reduced by 
thiols such as dithiothreitol (DTT) under physio-
logical conditions. 
H2N Se
CO2H
NH2
Se
CO2H
H2N SeH
CO2H  
  Selenocysteine, 1 Selenocystine, 2 
 The presence of a Sec residue in the active centre of 
an enzyme instead of a Cys confers a dramatic catalytic 
advantage. The lower pKa (5×2) of the selenol group 
in the active site as compared with thiol (8×0) may 
account for this catalytic advantage. Therefore, the 
selenol group is fully dissociated at physiological 
pH and the dissociated selenolate in enzyme’s active 
site is a much better nucleophile than the corre-
sponding thiolate. These properties and the unique 
redox behaviour of selenium make the Sec residues 
more reactive than Cys and, therefore, the Sec resi-
dues in selenoenzymes can be termed as “superreac-
tive cysteines”. A comparison of purified variants of 
formate dehydrogenase containing either a cysteine or a 
selenocysteine in the active site revealed that the 
overall catalytic efficiency is more than 300-fold 
higher for the selenium-containing variant.7 A drastic 
reduction of the activity was also found in genetically 
constructed variants of the type I deiodonase when 
they contained a cysteine rsidue in the position of the 
selenocysteine.39 In another case, replacement of the 
catalytically essential Cys residue in glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) with Sec con-
verted the phosphate dehydrogenase into a peroxi-
dase.40 
 
 
Scheme 1. Proposed model for Sec incorporation in 
Eukarya. (a) Synthesis of the selenium donor, monose-
lenophosphate; (b) conversion of seryl-tRNASec to seleno-
cysteyl-tRNASec; (c) formation of the complex for the 
cotranslational incorporati n of Sec. 
 
 Interestingly, unlike other amino acids present in 
proteins, Sec is not coded for directly in the genetic 
code. Alternatively, Sec is encoded by a UGA co-
don, which is normally a stop codon but, in these 
exc ptional proteins, is modified by a subsequent 
sequence in the mRNA molecule that encodes the 
enzyme. For specific Sec insertion at UGA codons, 
a unique selenocysteyl-tRNASec is synthesized from 
seryl-tRNASec using selenophosphate as the reactive 
selenium donor compound.41 Decoding of the UGA 
codon as Sec and its subsequent incorporation, therefore, 
requires a complex multi-component system and 
several reactions (scheme 1). These include: (a) the 
formation of the selenium donor, selenophosphate, 
from ATP and selenide, catalysed by the seleno-
phosphate synthetase-2 (SELD), which is a sele-
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noenzyme by itself; (b) a specific tRNA, called 
tRNA (Ser)Sec or SelC, which is first loaded with 
serine and then converted into Sec by selenocysteine 
synthase (SELA) using selenophosphate as selenium 
source; (c) a putative translation complex in analogy 
to the established complex in prokarya. The mRNA 
forms a characteristic secondary structure in the 3¢ 
nontranslated region, the Sec incorporating sequence 
(SECIS). The Sec-loaded tRNA(Ser)Sec is transferred 
to the ribosome A site and recognizes the UGA codon 
by its anti-codon ACU. The complex is stabilized 
via the interaction of putative SECIS-binding proteins 
(SelB) with the SECIS and the tRNA.42 
2.1 Monoselenophosphate, the selenium donor 
molecule 
The selenium donor for the nucleophilic addition during 
Sec incorporation has been identified as monoseleno-
phosphate.43 The mechanism of selenophosphate 
synthesis from ATP and selenide has been investigated 
in isotope-labelling experiments, and in various types 
of isotope exchange experiments. The multi-step 
process involves formation of a phosphorylated en-
zyme derivative and tightly bound ADP. Transfer of the 
enzyme phosphoryl group to selenium forms seleno-
phosphate and hydrolysis of the bound ADP gives 
orthophosphate and AMP as below. 
 
 ATP + E ® E-P[ADP], (1) 
 
 E-P[ADP] + SE– ® HSe-PO3H2 + E + AMP +Pi, 
  (2) 
 
 ATP + HSe– ® HSe-PO3H2 + PI + AMP. (3) 
 
Selenophosphate synthetase is a monomeric enzyme 
of 37 kDa. Analysis of the Escherichia coli enzyme 
suggests that a cysteine residue (Cys17) may be in-
volved in the catalysis.16,44 It is intriguing that enzymes 
from many other organisms contain a Sec in this po-
sition. A mechanism must therefore exist to circumvent 
the ‘chicken and egg’ situation that the product of the 
reaction of an enzyme is required for its own synthesis. 
It must be noted that several other organisms also 
produce selenophosphate synthetase analogues, but 
these enzymes contain an Arg or Thr residue in position 
17. One of such variants has been purified from 
Drosophila melanogaster; however, the protein has 
been found to be devoid of selenium-dependent se-
lenophosphate synthetase activity.44 
2.2 Conversion of seryl-tRNASec to selenocysteyl-
tRNASec 
The onoselenophosphate synthesized by seleno-
phosphate synthetase is used for the converstion of 
seryl-tRNASec into selenocysteyl-tRNASec by another 
enzyme called selenocysteine synthase encoded by the 
selA gene in E. coli.45 Although experimental evidence 
exists for such a reaction in various eukarya systems, 
the enzyme has yet to be identified.46 For various 
bacteria, selenocysteine synthase has been shown to 
be a homo-decamer with a molecular mass of about 
500 kDa.47 The reaction proceeds by the covalent 
binding of seryltRNASec to the pyridoxal phosphate 
of selenocysteine synthase, which to date is the only 
PLP enzyme to bind a nucleic acid. The elimination 
of a water molecule from the seryl moiety followed by 
reaction with monoselenophospate produces seleno-
cysteyl-tRNASec (scheme 2).48,49 
3. Synthetic methods to incorporate Sec into 
prot ins 
3.1 Native chemical ligation 
Synthetic introduction of Sec into peptides is an at-
tractive alternative to recombinant methods due to 
the complications associated with decoding the UGA 
stop codon described in the introduction. A number of
synthetic peptides and proteins have been prepared 
by solid phase peptide synthesis (SPPS) that incor-
porated selenocysteine by using Boc- or Fmoc-Sec 
(PMB)-OH.50 By using the native chemical ligation 
technique the ability to synthetically introduce a 
free selenol (or diselenide) into a peptide permits 
entry into larger peptides/proteins. In the selenocys-
t i e version of native chemical ligation, two ligation 
partners, one a C-terminal peptide thioester and the other 
a peptide containing an unprotected Sec/selenocystine 
at its N terminus, are mixed tog ther along with a 
reducing agent. After an initial trans selenoesterifi-
ation, a selenoester 1 is formed (scheme 3). This 
intermediate rearranges through an Se-to-N acyl shift 
to give the thermodynamically stable native peptide 
bond. Several recent model studies have shown the 
feaibility of this process. 
In order to achieve an effective native chemical 
ligation, suitably protected selenocysteine derivatives 
are required. Walter and co-workers reported one of 
the first syntheses of optically pure selenocysteine 
derivatives.51 A key step in the preparation inv lved 
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Scheme 2. Proposed reaction mechanism for the conversion of seryl-tRNASec to seleno-
cysteyl-tRNASec catalysed by selenocysteine syntha e.49 
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Scheme 3. Selenocysteine-mediated native chemical ligation. 
 
 
BocHN
OH
O
OH
DEAD
PPh3 O
OBocHN Ph2Se2
NaHB(OMe)3
BocHN
OH
O
SePh
TFA
Fmoc-OSu
TEA
FmocHN
OH
O
SePh
Fmoc-Sec(Ph)-OH 
Scheme 4. Synthesis of Fmoc-Sec(Ph)-OH via L-serine-b-lactone. DEAD = diethyl-azodicar-
boxylate, TFA = trifluoroacetic acid, TEA = triethylamine, Fmoc-Osu = 9-fluorenylmethoxycar-
bonyl succinate. 
 
 
the nucleophilic displacement of a O-tosylated L-
serine derivative. A later alternative approach was 
reported by Shirahama and co-workers who reduced 
diphenyl diselenide with sodium metal and reacted 
the resulting selenolate with tert-butoxycarbonyl 
(Boc) protected serine b-lactone.52 More recently, this 
approach has been modified by performing an in 
situ reduction of diphenyl diselenide with sodium 
trimethoxyborohydride [NaBH(OMe)3] (scheme 4).
53 
In this latter study, the Boc group was removed, fol-
lowed by 9-fluorenylmethoxycarbonyl (Fmoc) pro-
tection in a one-pot procedure to yield Fmoc-Sec 
(Ph)-OH, which was used for automated solid-phase 
peptide synthesis (SPPS). 
 Recently, an alternative synthetic route to seleno-
cysteine derivatives has been reported (scheme 5).54 
Three orthogonal protecting groups were used for 
the amino, carboxylate, and selenol functionalities 
that allowed their independent manipulation. The free 
carboxylate of Fmoc-Ser was converted to the allyl 
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Scheme 5. Improved scalable synthesis of Fmoc-Sec derivatives. 
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Scheme 6. Selenocysteine-mediated expressed protein ligation. X = recombinant target protein 
truncated at its C terminus. Y = synthetic peptide corresponding to the truncated C terminus. 
 
 
ester, followed by activation of the alcohol with p-
toluenesulfonyl chloride to provide 3. p-Methoxy-
benzyldiselenide (PMBSe)2, obtained by treating se-
lenium powder with super hydride followed by 
PMBCl, was reduced to the selenol with hypophos-
phoric acid. Without further purification, the resulting 
selenol was added to 3 under basic conditions to 
yield the fully protected selenocysteine derivative. 
Selective deprotection of the carboxylate with catalytic 
palladium and morpholine gav  4 in good yield. 
3.2 Expressed protein ligation 
Expressed protein ligation (EPL), a powerful exten-
sion of native chemical ligation, was first reported 
in 1998 and has become increasingly popular in recent 
years for protein engineering. With the success of Se-
mediated native chemical ligation, it became clear 
that Sec could also be used at the point of ligation in 
expressed protein ligation.55 The process of seleno-
cysteine-mediated EPL is briefly outlined in scheme 
6. A target protein truncated at its C erminus is 
overexpressed in E. coli as a fusion to an intein domain 
and affinity tag (either a hexa-His t g or chitin binding 
domain, CBD). The cell lysate is passed through the 
affinity column to bind the target protein and separate 
it from other cellular constituents. Inteins self-catalyse a 
rearrangement reaction from an amide to a thioester 
at a cysteine residue within their sequence. When an 
external thiol is added to the resin, a trans-thioesteri-
fication takes place that cleaves the truncated target 
protein from the resin while leaving the intein attached. 
Additi n of an unprotected synthetic peptide with Sec 
at its N terminus initiates another trans-thioesteri-
fication, followed by an Se-to-N acyl shift to yield a 
fully deprotected mutant protein wi h a Sec incorp-
rated at a specific site within the polyp ptide. 
4. Glutathione peroxidases (GPx) 
Glutathione peroxidases (GPx) are antioxidant sele-
oenzymes protecting various organisms from oxidative 
tresses by catalyzing the reduction of hydroperoxides 
at the expense of GSH.56,57 The GPx superfamily 
contains four types of enzymes, the classical ytosolic 
GPx (cGPx), phospholipid hydroperoxid  GPx 
(PHGPx), plasma GPx (pGPx), and gastrointestinal 
GPx (giGPx), all of which require selenium in their 
active sites for the catalytic activity.58–62 The reactivity 
of these enzymes differs considerably depending upon 
the hydroperoxides and thiol cofactor. The classical 
GPx utilizes exclusively GSH as reducing substrate 
MB 
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for the reduction of H2O2 and a limited number of 
organic hydroperoxides such as cumene hydro-
peroxide and tert-butyl hydroperoxide. The PHGPx 
also uses GSH as physiological reducing substrate, 
but the hydroperoxide substrate specificity is more 
broad. This enzyme is active on all phospholipid hy-
droperoxides, fatty acid hydroperoxides, cumene 
hydroperoxide, tert-butyl hydroperoxide, cholesterol 
hydroperoxides, and H2O2.
63 On the other hand, the 
hydroperoxide substrate specificity of pGPx is more 
restricted. Although pGPx can reduce H2O2 and or-
ganic hydroperoxides, it is approximately 10 times 
less active than the cGPx. In contrast to the cGPx, 
GSH is a poor reducing substrate for this enzyme. 
Since the concentration of reduced thiol groups in hu-
man plasma is very low, it is quite unlikely that GSH is
the reducing substrate for the plasma enzyme. Alter-
natively, the extracellular thioredoxin reductase, 
thioredoxin, or glutaredoxin could be reasonable 
candidates.64 
 The GPx catalytic site includes a Sec residue in 
which the selenium undergoes a redox cycle involving 
the selenol (ESeH) as the active form that reduces 
hydrogen peroxides and organic peroxides. The selenol 
is oxidized to selenenic acid (ESeOH), which reacts 
with reduced glutathione (GSH) to form a selenenyl 
sulphide adduct (ESeSG). A second glutathione then 
regenerates the active form of the enzyme by attacking 
the ESeSG to form the oxidized glutathione (GSSG) 
(scheme 7). Thus, in the overall process, 2 equiv of
glutathione are oxidized to the disulphide and water, 
while the hydroperoxide is reduced to the corre-
sponding alcohol. In the presence of an excess hy-
droperoxide, the selenium centre in GPx may be 
overoxidized to produce seleninic acid (ESeO2H) and 
selenonic acid (ESeO3H). However, such species are 
believed to lie off the main catalytic pathway. 
 
ROOH
ROH
H2O
ESeH
ESeOH
ESeSG
GSH
GSH
GSSG
 
 
Scheme 7. Proposed catalytic mechanism for the reduc-
tion of hydroperoxides by GPx. 
 The arrangement of the amino acid residues in the 
active site of GPx shows some interesting features. 
It is evident from various studies that two amino acid 
r sidues, that is tryptophan and glutamine, appear in 
identical positions in all known members of the GPx 
family.58 According to the three-dimensional structure 
established for bovine cGPx, these residues could 
constitute a catalytic triad in which the selenol group 
of the selenocysteine is both stabilized and activated 
by hydrogen bonding with the imino group of the 
tryptophan (Trp) residue and with the amido group 
of the glutamine (Gln) residue (figure 1).65 The crystal 
structure of human plasma GPx has also been de-
ter ined and crystallographically refined at 2×9 Å 
resolution.66 Although the overall active site archi-
tecture of the human pl sma enzyme is similar to that 
of the cytoplasmic enzyme, the environment close to 
the selenocysteine residues is quite different in the two 
enzymes. Approximately only half of the residues 
close to the selenocysteine residue within a range of 
10 Å are conserved in both enzymes. The residues 
conserved in the human plasma enzyme are Phe76, 
Gln79, Arg95, Trp153, Phe155, Asn154 and Arg173. 
Of these residues, Gln79 and Trp153 are located within 
hydrogen bonding distance of the selenium atom and 
have been suggested to play functional roles in ca-
talysis. As mentioned already, these two residues 
re in fact conserved in the whole GPx superfamily 
and probably account for the similarities in their 
catalytic mechanisms. 
 The chemical aspects of the reduction of hydro-
peroxide by GPx have been extensively studied with the 
help of model compounds. These include anti-
inflammatory drug ebselen, a variety of substituted 
diaryl selenides and diselenides, N-S  heterocycles, 
th  artificial selenoenzyme selenosubtilisin, seleno-
peptides, and other types of selenium compounds.67–78 
Hilvert et al have shown that the reduced form of 
selenosubtilisin is strongly stabilized by nearby his-
tidine residues.79 Because the enzyme-bound selenol is 
 
 
 
Fig re 1. The active site of GPx showing Sec-Trp-Gln 
catalytic triad. 
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Scheme 8. Biochemical deiodination of thyroxine catalysed by iodothyronine deiodinases. 
 
 
NN
His64
H H+ Se
Sec221
H2N Asn
155
O
..... .....
 
 
Figure 2. Stabilization of the selenolate form of seleno-
subtilisin. 
 
 
deprotonated by His64 to form a selenolate-imidazo-
lium ion pair at all accessible pH values, it is expected 
to be highly reactive and therefore susceptible to 
oxidation by hydroperoxides. Another amino acid 
residue, Asn155, is also expected to play an impor-
tant role in the stabilization of the selenolate (figure 2). 
Similarly, the active site selenol (Sec149) in seleno-
GAPDH interacts with a histidine residue (His176) 
to form an efficient selenolate-imidazolium ion pair.79 
In agreement with the role of Trp and Gln in GPx 
catalysis and the importance of His residues in the 
reduction of hydroperoxides by selenosubtilisin, basic 
amino groups in the close proximity to selenium hav 
been shown to play a significant role in m dulating the 
antioxidant properties of synthetic selenium com-
pounds.78 
5. Iodothyronine deiodinases (ID)
The thyroid gland, in response to stimulation by TSH, 
produces thyroxine (T4) as the main secretory product 
that undergoes enzymatic outer-ring deiodination to 
produce the biologically active hormone, 3,5,3¢-triiodo-
thyronine (T3), and this reaction is catalysed by type 
I iodothyronine deiodinase (ID-I), a selenocysteine-
containing integral membrane enzyme80 present in the 
highest amounts in liver, kidney, thyroid and pitui-
tary. The thyroid gland also produces an inactive 
metabolite rT3 by inner ring deiodination. The triiodo 
derivatives T3 and rT3 are further metabolized by 
inner ring and outer ring deiodination, respectively, 
by ID-I, ID-II and ID-III to produce the inactive meta-
boilite T2 (3,3¢-T2, 3,5-T2 and 3¢,5¢-T2) (scheme 8). 
 The 5¢-deiodination catalysed by ID-I is a ping-
pong, bisubstrate reaction in which the selenol (or 
selenolate) group of the enzyme (E-SeH or E-Se–) 
first reacts with thyroxine (T4) to form a selenenyl 
iodide (E-SeI) intermediate. Subsequent reaction of 
the selenenyl iodide with an as yet unidentified in-
tracellular cofactor (DTT in vitro) completes the 
catalytic cycle and regenerates the enzyme active 
site (scheme 9). It is known that the anti-thyroid 
drug, 6-n-propyl-2-thiouracil (PTU), inhibits the ac-
tivity of the enzyme probably by reacting with the 
selenenyl iodide intermediate and the gold-containing 
drugs such as gold thioglucose (GTG) inhibits the 
deiodinase activity by reacting with the selenol group 
of the native enzyme. 
6. Anti-thyroid drugs 
As mentioned in the previous section, in healthy 
humans the thyroid gland produces predominantly the 
prohormone T4, which is enzymatically deiodinated 
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Scheme 9. Proposed mechanism for the deiodination of thyroxine by ID-1 and inhibition 
of ID-1 by n-propyl-2-thiouracil (PTU) and gold thioglucose (GTG).
 
 
to provide the biologically active hormone T3 and 
other inactive species. Although the enzymatic deiodi-
nation is important for the functioning of the thyroid 
gland, the activation of thyroid-stimulating hormone 
(TSH) receptor by auto-antibodies leads to an over-
production of thyroid hormones. In addition, these 
auto-antibodies also stimulate ID-I and proba ly ID-
II, which then together produce relatively more T3. 
As these antibodies are not under pituitary feedback 
control, no negative influence on thyroid activity is 
exerted and therefore hyperthyroidism persists. Under 
these conditions, the overproduction of T3 is c ntrolled 
by specific inhibitors, which either block the thyroid 
hormone biosynthesis or reduce the conversion of 
T4 to T3. An interesting class of such inhibitors is 
the thiourea drugs, 6-n-propyl-2-thiouracil (5, PTU), 
6-methyl-2-thiouracil (6, MTU), methimazole (7, 
MMI) and carbimazole (8, CBZ). 
 
5, R = nPr
6, R = Me 7 8
N N
S
H H
OR
N N
S
Me H N N
S
Me O
O
 
 
 Although these compounds are the most commonly 
employed drugs for the treatment of patients with 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
hyperthyroidism, the detailed mechanism of their action
is still not clear. According to the ini ially proposed 
mechanism, these drugs form stable electron donor-
acceptor complexes with diiodine and divert oxidized 
iodides away from thyroglobulin, which effectively 
reduces the thyroid hormones biosynthesis.81 I  has 
been proposed in the second mechanism that these 
drugs coordinate to the thyroid peroxidase (TPO), a 
heme enzyme which catalyses the oxidation of iodides 
and the coupling of iodothyrosine residues of thyroglo-
bulin, thereby blocking the thyroid hormone synthesis 
(figure 3).82 
 
Figure 3. A hypothetical model for the coordination of 
thiourea drugs to the Fe-centre of TPO. 
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7. Inhibition of iodothyronine deiodinases 
After the discovery that the ID-I is responsible for 
the activation of thyroxine, it has been reported that 
PTU can also block the conversion of T4 to T3 by 
reacting with the selenenyl iodide intermediat  (E-
SeI) of ID-I to form a selenenyl sulphide (figure 4) 
as a dead end product.83 In erestingly, PTU does not 
block the activity of other two selenoenzymes (ID-II 
and ID-III) under normal conditions and the reason 
for the insensitivity of PTU towards these two en-
zymes is still unknown. Recent biomimetic studies 
on the inhibition of ID by anti-thyroid drugs have 
been focused on three aspects: (i) Experimental 
verification for the mechanism of the inhibition of 
ID-I by PTU and MTU, (ii) identification of the 
possible reason for the insensitivity of certain deio-
dinases towards PTU and MTU, (iii) possible expla-
nation for the lower inhibitory activity of MMI 
towards ID-I compared with that of PTU and MTU.84 
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 The reactivity of Se-I species towards anti-thyroid 
drugs has been experimentally verified by du Mont 
et al84 with the help of synthetic selenenyl iodides. 
When “PhSeI” (0×5 Ph2Se2.I2) and 9, which are known 
to disproportionate in solution to diselenide and iodine
or their adducts, were treated independently with 
stoichiometric amounts of PTU or 6-methyl-2-thiouracil 
(MTU) in the presence of triethylamine, both the re-
actions afforded the corresponding diselenides, rather 
than the selenenyl sulphides, as the only products.84a 
This indicates that the unstable selenenyl iodides 
PhSeI and 9 are reduced by PTU and MTU to the 
corresponding diselenides (and not the PTU/MTU 
derivatives). These properties of PhSeI and 9 therefore 
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Figure 4. Synthetic models for the Se-I intermediate of 
ID-I. 
resemble the inhibitory action of PTU-insensitive 
deiodinases. In the absence of triethylamine, selenenyl 
iodide 10 reacted with PTU and MTU much more 
slowly than the internally chelated compound 11. 
Although compound 11 reacted rapidly with PTU 
and MTU under similar experimental conditions, it 
unexpectedly afforded the corresponding diselenide 
as the major product. This result indicates that the 
HI produced during the reaction may act as a catalyst 
for the diselenide formation. However, in the presence 
of triethylamine, no diselenide is formed and both 
10 and 11 reacted rapidly with PTU and MTU to give 
the desired selenenyl sulphides 12 and13, respectively 
(figure 4).84 
 The crucial amino-acid residues responsible for 
binding inhibitors or the details concerning the nature 
of enzyme-inhibitor interactions have not yet become 
available. A careful analysis of the active site features 
of ID-I reveals that the presence of N–H groups in the 
thiourea drugs is essential not only for the reactivity 
of the drugs but also for the stability of the selenenyl 
sulphide adducts formed with the enzyme. The potent 
inhibitory effects of PTU and MTU towards ID-I 
may be due to the presence of –N(H)–C(=O)– func-
tionality that could form hydrogen b nds with nearby 
amino acid residues after the formation of a stable 
selenenyl sulphide, making the active site not accessible 
for further reactions. In contrast, MMI does not have 
any additional N-H groups after the formation of a 
selenenyl sulphide and therefore cannot exhibit any 
stabilizing interactions with the nearby amino acid 
residues. In agreement with this, the crystal structure 
of 12 shows that the Se–S bond in this compound is 
stabilized by intermolecular hydrogen bonds (figure 5). 
8. Thioredoxin reductases (TrxR) 
Thioredoxin reductase (TrxR, EC 1.6.4.5) is a member 
of the pyridine nucleotide–disulphide oxidoreductase 
family.85 Enzymes of this family, such as glu-
tathione reductase (GR), lipoamide dehydrogenase, 
and trypanothione reductase, form homodimers, and 
each subunit contains a redox-active disulphide 
bond and a tightly bound FAD molecule. TrxR ca-
talyses reduction of thioredoxins (Trx) by NADPH. 
Trxs are a group of small (10–12 kDa) ubiquitous 
redox-active proteins, which have a conserved –
Trp–Cys–Gly–Pro–Cys–Lys– catalytic site that un-
dergoes reversible oxidation-reduction of the two 
Cys residues. The redox activity of this catalytic site 
is necessary for the biological activity of Trx.86,87 
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Figure 5. The crystal structure of 12, showing intermolecular hydrogen bonds.84 
 
 
Table 2. Roles of Trx in mammals. 
Role Comments 
 
Redox regulation of transcription Different transcription factors are either activated or inhibited by 
 factors, e.g. NFkB, AP-1   Trx, which also may exert different activities in nucleus  
   compared to cytosol 
Regulation of apoptosis  Trx makes a complex with ASK1, prevents downstream signaling  
   for apoptosis 
Immunomodulation Extracellular Trx is both a co-cyt kine and chemokine and a  
   truncated form stimulates eosinophiles 
Pregnancy Intracellular and extracellular synthesis of Trx from cytotropho-
   blasts assist implantation and establishment of pregnancy 
Birth Protection from hyperoxia at birth by induction of Trx 
CNS Trx secreted from glial cells promotes neuronal survival at  
   ischemia/reperfusion 
 
 
Although it is beyond the scope of this review to 
thoroughly describe all of the functions of mammal-
ian Trx proteins, some of the major functions are to 
supply reducing equivalents to enzymes such as ribo-
nucleotide reductase and thioredoxin peroxidase, and, 
through thiol-disulphide exchange, to reduce key 
Cys residues in certain transcription factors, result-
ing in their increased binding to DNA and altered 
gene transcription (table 2).88 
 TrxR-catalysed reduction of Trx utilizes NADPH 
as cofactor. The reduced form of Trx provides re-
ducing equivalents to (i) Trx peroxidase, which breaks 
down H2O2 to water, (ii) ribonucleotide reductase, 
which reduces ribonucleotides to deoxyribonucleotides 
for DNA synthesis, and (iii) transcription factors, which 
leads to their increased binding to DNA and altered 
gene transcription (figure 6). In addition, Trx increases 
cell growth and inhibits apoptosis. The mammalian 
TrxRs have a higher molecular mass (55 kDa) and a 
very broad substrate specificity in contrast to the 
smaller (35 kDa) specific enzymes represented by 
the well-characterized E. coli TrxR.89 The mamma-
lian enzymes are selenoenzymes, which can react 
not only with Trx from different species but also 
with a variety of non-disulphide substrates, such as 
selenoglutathione, selenite, ascorbic acid, S-nitro-
soglutathione, hydroperoxides and peroxynitrite.90 
The presence of Sec in the these enzymes is essential 
because its replacement with Cys results in a mutant 
r t TrxR enzyme with about 1% activity with Trx as 
substrate.91,92 
 T e mammalian TrxRs possess two redox active 
centr s: One consisting of Cys59/Cys64 adjacent to 
th  flavin ring of FAD and the other consisting of 
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Figure 6. Functions of TrxR in the cell.
 
 
Cys497/Sec498 near the C-t rminus. The proposed 
mechanism for the reduction of Trx by TrxR is 
summarized in scheme 10. According to this mecha-
nism, the first step is the reduction of the selenenyl 
sulphide to produce the corresponding selenol (or 
selenolate). The selenol (or selenolate anion) attacks 
the disulphide bond of Trx, resulting in the forma-
tion of a TrxR–Trx-mixed selenenyl sulphide. The 
Se–S bond in this intermediate is cleaved by Cys497 
to regenerate the selenenyl sulphide, which could be 
reduced further by the Cys residue of the nearby 
subunit. In this conversion, the conserved Cys-497-
Sec-498 motif acts as a second redox centre and the 
electrons are transferred from the redox-active di-
sulphide via the redox centre at the C terminal to the 
substrate, Trx.91–93 
 The conformation of the C-terminal can be modelled 
in such a way that it approaches the redox-active di-
sulphide Cys59–Cys64 close enough for electron 
transfer without steric clashes, decreasing the distance 
between Cys59 and Cys497 from 12 Å to 3 Å. This 
co formational change involves mainly residues 
Ser495–Cys,498 where the largest movement is that of 
Cys497 (about a 5-Å displacement of the Ca-atom). 
The charge interaction between the C-terminal carboxyl 
group of Gly499 and the side chain of Lys29 can be 
maintained in the two conformations. A careful analysis
of the active site features of mammalian TrxR mu-
tant reveals that one or more histidine residues near 
the Se–S and S–S bonds may play crucial roles in 
the catalysis (figure 7). 
 In such a model of the oxidized form of the Cys497–
Sec498 motif, the selenium atom would be located 
very close to the side chain of the conserved His472, 
and the imidazole group could participate in proton 
transfer to Cys497. After reduction, the C-terminal tail 
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Scheme 10. Proposed catalytic mechanism for the reduction of Trx by mammalian TrxR.
 
 
 
 
Figure 7. The active site of the Sec498Cys mutant of rat TrxR (PDB code: 1H6V).85 
 
 
could then move away from the catalytic site to a 
position at the surface of the enzyme and interact 
with the bound substrate, Trx. The model of the TrxR–
Trx complex is consistent with a mechanistic scenario 
for the dithiol–disulphide exchange reaction put 
forward previously.92 In this step of the reaction, the 
selenolate anion attacks the disulphi e of Trx. The 
resulting enzyme, Trx-mi ed selenenyl sulphide, is then 
attacked by Cys497 to regenerate the selenenyl sul-
phide. 
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9.1 Reduction of hydroperoxides by Trx system 
A number of recent studies suggest that the mam-
malian Trx system can reduce hydroperoxide substrates 
and thus mimic the properties of GPx. As already 
mentioned, the hydroperoxide substrate specificity 
of plasma GPx is highly restricted. This enzyme can 
reduce H2O2 and organic hydroperoxides, but its acti-
vity was found to be much lower than that of the 
cGPx. In addition, the tripeptide GSH is a poor re-
ducing substrate for this enzyme. This led to the as-
sumption that TrxR, Trx, or glutaredoxin may be 
involved in the reduction of peroxides by the plasma 
enzyme.64 In agreement with this, Holmgren et al94 
have shown that human TrxR and NADPH in the 
presence or absence of Trx serve as efficient elec-
tron donors to human GPx. In addition, they have 
also shown that the human placenta TrxR directly 
reduces lipid hydroperoxides by NADPH and the 
rate of this reaction can be accelerated by the addition 
of selenocystine.95 It is believed that the catalytic 
mechanism proceeds throug  the formation of a 
catalytically active selenol, which is produced by 
the reduction of the diselenide bond in selenocystine 
by TrxR. 
 Holmgren et al96 have proposed the mechanism 
for the reduction of lipid peroxides and H2O2 by the 
mammalian Se-containing TrxR (scheme 11), which 
is similar to the mechanism proposed for the reduc-
tion of Trx. According to this mechanism, the selenenyl 
sulphide form of the enzyme receives an electron 
from NADPH to cleave the Se–S bond and produce 
the selenol-thiol form. Because the selenol is expected 
to be dissociated and more nucleophilic than the thiol 
group, the selenol (or selenolate) can reacts with H2O2  
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Scheme 11. Proposed mechanism for the reduction of 
hydroperoxides by mammalian TrxR. 
much faster than the thiol to produce the corresponding 
selenenic acid (E-SeOH). The next step of the catalytic 
cycle should be the attack of one of the cysteine thi-
ols (mo t likely Cys497) at the selenenic acid to 
produce water and to reform the selenenyl sulphide. 
A second thiol (most likely Cys59 from the other 
subunit) would attack the Se–S linkage to regenerate 
the selenol. 
9.2 Thioredoxin reductase as drug target 
The Trx system is of medicinal interest due to its 
inherent role as a broad based indicator of diseases 
such as AIDS, rheumatoid arthritis, and certain forms 
of cancer and represents an attractive target for further 
pharmacological examination. In recent years, the 
biological screening has led to the identification of a 
number of small organic and organometallic com-
pounds as chemotherapeutic inhibitors of TrxR (fig-
ure 8).97 Although the early studies have shown that 
nitrosoureas such as BCNU can be effective irre-
versible inhibitors of TrxR,98 these compounds are quite 
toxic, relatively non-selective, and known to alkylate 
DNA. However, certain alkyl 2-imidazolyl disulphides 
such as PX-12 and the symmetrical cyclopentanone 
NSC 131233 have been found to be good inhibitors 
through screening by a COMPARE analysis from 
over 50,000 compounds tested by the National Cancer 
Institute. PX-12 is currently in Phase I clinical trials 
and demonstrated antitumor activity in immunodeficient 
mice xenograft models.99 Some of the clinically used 
drugs that act on TrxR are summarized in table 3. 
 Halonitrobenzenes such as 1-chloro-2,4-dinitro-
benzene irreversibly inhibit the human TrxR with a 
concomitant induction of an NADPH oxidase activity, 
producing superoxide (scheme 12).107 A model ex-
plaining the reactivity of dinitrohalobenzenes with 
thioredoxin reductase is presented, involving dini-
trophenyl-derivatization of both the selenocysteine 
residue and its neighbouring cysteine residue, reduc-
tion by NADPH of the enzyme-bound flavin in dini-
trophenyl-alkylated enzyme (DNB-TrxR), followed by 
two consecutive one-electron transfers from the flavin 
to nitro groups of the DNB-moieties in DNB-TrxR, 
forming nitro anion radicals. The nitro radicals react 
with oxygen to form superoxide, again generating d p-
TrxR with an oxidized flavin, which may then fol-
low another cycle of NADPH-dependent superoxide 
production. Halodinitrobenzenes are well known for 
their immunostimulatory properties. Here it is proposed 
that the inflammatory components of this immuno-
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Figure 8. Chemotherapeutic inhibitors of the Trx/TrxR system. 
 
 
Table 3. Clinically applied drugs with postulated effects on TrxR. 
TrxR inhibitor Comment Ref. 
 
Carmustine (BCNU) and Very effective irreversible TrxR inhibitors; however, not selective, 100 
 other nitrosoureas  since mechanistically related enzymes are also inactivated and  
   DNA is alkylated 
Cisplatin Consistently, high Trx-levels appear to be involved in cisplatin 101 
   resistance 
Anthracyclines The inhibitory effects published for the rat enzyme wre not 102 
   reproducible with the human enzyme in our hands  
Azelaic acid (dicarboxylic acids) The original studies were partly conducted with E. coli enzyme. 103 
   We found no inhibition of human h-TrxR 
13-cis-Retionic acid Results obtained with E. coli enzyme were mixed with data from 103, 104 
   human enzyme. All-trans retionic acid increases TrxR levels  
   when apoplied with interferon 
1-Chloro-2,4-dinitrobenzene  Experimental drug in dermatology with promises for clinical use 102, 103, 105 
ATG, Auranofin Selective tight-binding inhibitors, the formal Ki for auranofin 106 
   being 4 nM 
 
 
stimulation can be mediated by interaction with the 
thioredoxin system, via effects on cell function by 
superoxide production, oxidative stress and increased 
extracellular levels of thioredoxin. 
 Organic gold complexes such as aurothioglucose 
(ATG), auranofin, which are commonly used for the 
treatment of rheumatoid arthritis, were also discov-
ered to be potent inhibitors of Trx/TrxR.106 It has 
been shown that the gold free thioglucose moiety in 
these compounds does not inhibit the enzyme. Fur-
thermore, gold-chelating agents such as BAL prevent 
and reverse the inhibition of TrxR caused by three 
different compounds that have only the gold moiety 
in common. From these studies it is clear that the 
binding of gold and not the organic moiety to the 
enzyme is responsible for the inhibition of TrxR. It is 
known that selenols can bind heavy metal ions much 
stronger than thiols. This leads to an assumption that  
the C-terminal redox-active Cys497/Sec498 centre of TrxR 
may be the target of the inhibitors.107 In agreement 
with this, the structurally and mechanistically closely 
related but selenium-free enzyme GR has been found to 
be far less sensitive to the inhibition by gold complexes. 
10. Summary and future perspectives 
The research progress in the biochemistry of sele-
nium over the last two decades led to the identification, 
clon ng and functional characterization of a number of
selenoenzymes with widely varied catalytic potential, 
and the key events of selenoprotein biosynthesis have 
been elucidated. The biomimetic studies on seleno-
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Scheme 12. Production of superoxide by TrxR.107 
 
 
enzymes have been focused mainly on glutathione 
peroxidase (GPx) due to the fact that the structure 
and catalytic mechanism of this enzyme is well known. 
However, the insights gained from the previous 
model studies on GPx may provide a solid basis not 
only for the development of more efficient GPx mimics 
but also for the design and synthesis of organoselenium 
compounds that could mimic the action of other sele-
noenzymes uch as iodothyronine deiodinase and 
thioredoxin reductase for which successful synthetic 
mimics have not yet been developed. The reactivity 
of selenocysteine residues in selenoenzymes towards 
metal-containing compounds such as goldthioglucose 
may be utilized in the design and synthesis of metal-
based drugs. 
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